. SERCA2a activity correlates with the forcefrequency relationship in human myocardium. Am J Physiol Heart Circ Physiol 278: H1924-H1932, 2000.-The present investigation addresses whether protein expression and function of sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA2a) and phospholamban (PLB) correlate in failing and nonfailing human myocardium. SERCA2a activity and protein expression, PLB phosphorylation, and the force-frequency relationship (FFR) have been determined in right atrium (RA) and left ventricle (LV) from nonfailing (NF, n ϭ 12) and terminally failing [dilated cardiomyopathy (DCM), n ϭ 12] human hearts. Only in LV of DCM hearts was SERCA2a activity significantly decreased [maximal turnover rate (V max ) ϭ 196 Ϯ 11 and 396 Ϯ 30 nmol · mg Ϫ1 · min Ϫ1 in LV and RA, respectively], whereas protein expression of SERCA2a in the different chambers was unchanged in NF (3.9 Ϯ 0.3 and 3.2 Ϯ 0.4 densitometric units in LV and RA, respectively) and DCM hearts (4.8 Ϯ 0.8 and 3.4 Ϯ 0.1 densitometric units in LV and RA, respectively). Phosphorylation of PLB was higher in LV than in RA in NF (Ser 16 : 180.5 Ϯ 19.0 vs. 56.8 Ϯ 6.0 densitometric units; Thr 17 : 174.6 Ϯ 11.2 vs. 37.4 Ϯ 8.9 densitometric units) and DCM hearts (Ser 16 : 132.0 Ϯ 5.4 vs. 22.4 Ϯ 3.5 densitometric units; Thr 17 : 131.2 Ϯ 10.9 vs. 9.2 Ϯ 2.4 densitometric units). SERCA2a function, but not protein expression, correlated well with the functional parameters of the FFR in DCM and NF human hearts. Regulation of SERCA2a function depends on the phosphorylation of PLB at Ser 16 and Thr 17 . However, direct SERCA2a regulation might also be affected by an unknown mechanism. heart failure; phospholamban phosphorylation; sarco(endo) plasmic reticulum calcium-adenosine 5Ј-triphosphatase
in the myocardium from failing hearts (27) . The structural basis for this reduced SERCA2a activity is not yet resolved. Downregulation of protein expression of SERCA2a and its regulatory protein phospholamban in myocardium from patients with terminal heart failure seems not to be the case (15, 18, 27) , although a small reduction of protein expression was also reported (9, 17) . SERCA2a activity is under inhibitory control of phospholamban (10, 12) , and phosphorylation of phospholamban relieves the inhibitory action on SERCA2a activity (29) . Therefore, lower phosphorylation could be the key problem for decreased SERCA2a activity in human heart failure. Recently, Schwinger et al. (23) showed blunted protein kinase A (PKA)-dependent phosphorylation at the Ser 16 site of phospholamban in failing human cardiac preparations, which contributes to the decreased Ca 2ϩ sensitivity of SERCA2a. Although alterations of Ca 2ϩ handling in the failing myocardium are not homogenous in different chambers of the heart, investigations are widely restricted to the left ventricle (LV). Few reports on Ca 2ϩ homeostasis and FFR in the atria from failing hearts are available. Besides the negative FFR in the LV of terminally failing hearts, a positive FFR in atria has been reported (25) .
Thus we investigated the function and protein expression of SERCA2a as well as the phosphorylation status of phospholamban in ventricular and atrial myocardium to analyze the regulation of protein expression and function in human heart failure in atria and ventricles. Moreover, we addressed whether SERCA2a activity, protein expression of SERCA2a and phospholamban, or phosphorylation status correlates with FFR in normal and diseased human myocardium in ventricular and atrial myocardium.
METHODS

Patients
Myocardium from terminally failing human hearts (LV myocardium, n ϭ 12) was obtained from patients with terminal heart failure (New York Heart Association stage IV) during cardiac transplantation (6 men and 6 women, 45 Ϯ 14 yr old, 28 Ϯ 5% ejection fraction) due to idiopathic dilated cardiomyopathy (DCM). The preoperative diagnosis was DCM in all patients. The hemodynamic data of the patients with heart failure were assessed before transplantation. For DCM patients, right atrial (RA) mean pressure was 9 Ϯ 6 mmHg, right ventricular systolic, diastolic, and mean pressures were
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 50 Ϯ 12, 8 Ϯ 4, and 13 Ϯ 5 mmHg, respectively, mean pulmonary arterial pressure was 35 Ϯ 7 mmHg, mean pulmonary artery wedge pressure was 23 Ϯ 10 mmHg, and LV end-diastolic pressure was 20 Ϯ 4 mmHg. End-diastolic volume in the LV was 314 Ϯ 19 ml, and cardiac output was 2.4 Ϯ 1.1 l/min. Echocardiographic data showed increased diameters of the RA (49 Ϯ 5 mm) and LV (69 Ϯ 13 mm). Patients were on regular medication with vasodilators (nitrates and angiotensin-converting enzyme inhibitors), cardiac glycosides, and diuretics. None of the patients had received a Ca 2ϩ antagonist within 7 days of surgery or ␤-adrenoceptor agonists within 48 h of surgery. Patients gave written informed consent before the operation. As controls, we used nonfailing (NF) hearts from brain-dead organ donors (n ϭ 12, 6 men and 6 women, 43 Ϯ 11 yr old) where transplantation of the heart was not possible because of suspected chest trauma after resuscitation under emergency conditions, positive cytomegalovirus titers, or technical reasons. Absence of heart disease was verified by normal electrocardiogram, absence of cardiovascular medication, and normal pump performance by echocardiography, and the consultant cardiologist recommended the heart acceptable for transplantation. Echocardiographic data showed normal diameters of the RA (39 Ϯ 3 mm) and LV (48 Ϯ 7 mm). Hemodynamic data were available in most cases of the NF organ donors: mean RA pressure was 7 Ϯ 2 mmHg, right ventricular systolic, diastolic, and mean pressures were 26 Ϯ 8, 4 Ϯ 2, and 8 Ϯ 2 mmHg, respectively, mean pulmonary arterial pressure was 17 Ϯ 4 mmHg, mean pulmonary artery wedge pressure was 14 Ϯ 3 mmHg, and cardiac output was 5.9 Ϯ 1.0 l/min.
Muscle Strip Preparation
After explantation, hearts were kept in cardioplegic Brettschneider solution (in mmol/l: 15 NaCl, 10 KCl, 4 MgCl 2 , 180 histidine hydrochloride, 2 tryptophan, 30 mannitol, and 1 potassium dihydrogen oxoglutarate) at 4°C during transportation between the cardiac surgery operation room and the research laboratory. On arrival in the laboratory, hearts were dissected in chilled Brettschneider solution, and part of the tissue was immediately shock frozen in liquid nitrogen and stored at Ϫ80°C until further use. Muscle strips were placed in 75-ml organ baths containing gassed (95% O 2 -5% CO 2 ) Tyrode solution (in mmol/l: 119.8 NaCl, 5.4 KCl, 1.05 MgCl 2 , 1.8 CaCl 2 , 22.6 NaHCO 3 , 0.42 NaH 2 PO 4 , 5.05 glucose, 0.28 ascorbic acid, and 0.05 Na 2 -EDTA) at 37°C. Stimulation was applied with two platinum electrodes (with variable frequency, 5-ms pulse duration, 5 V) with a Grass S88 stimulator. After 45 min of equilibration, the isometric force of contraction was measured with a force transducer (W. Fleck and FMI) and recorded with a Gould recorder. The experimental protocol was carried out according to the method described previously in detail (26) .
Tissue Preparation
For Western blot and SERCA2a activity measurement, homogenization and crude membrane preparation were performed as previously described (20) . Briefly, 0.5-1 g of myocardium from the free LV wall or the RA was powdered in liquid nitrogen and slowly thawed on ice in three volumes of chilled preparation buffer (in mmol/l: 300 sucrose, 1 phenylmethylsulfonyl fluoride, 20 PIPES, 10 EDTA, and 50 NaH 2 PO 4 , pH 7.4), as previously described (20) . Care was taken to dissect myocardial tissue from connective tissue, vessels, and epicardium. Samples were minced with three 30-s strokes with an Ultraturrax (Janke und Kunkel, IKAWerke, Staufen, Germany) after homogenization with a glassTeflon potter (Braun Melsungen, Melsungen, Germany) at constant temperature of 4°C. The resulting homogenate was further diluted with the same volumes of a storage buffer containing (in mmol/l) 400 sucrose, 5 HEPES, 5 Tris, 10 EDTA, and 50 NaH 2 PO 4 , pH 7.2, frozen in liquid nitrogen, and stored at Ϫ80°C until use in Western blot experiments. After homogenization, crude membranes (U3) were purified for SERCA2a activity assay with one 8,000-g centrifugation step (model JA 20, Beckman Instruments, Mü nchen, Germany) for 20 min. Supernatants were filtered through four layers of gauze and centrifuged for 60 min at 100,000 g (35,000 rpm; Sorvall A 641, DuPont Nemours, Bad Nauheim, Germany), as previously described (20) . Finally, crude membranes were resuspended in the storage buffer as described above, frozen in liquid nitrogen, and stored at Ϫ80°C until use. Protein content was measured according to Bradford's assay (3).
SERCA2a Activity
SERCA2a activity was determined with an enzymecoupled assay according to the method of Chu et al. (4) . The reaction was catalyzed by SERCA2a, in combination with pyruvate kinase and lactate dehydrogenase in the presence of Ca 2ϩ ionophore A-23187 (1 µmol/l). The oxidation of NADH was monitored continuously by the decrease in absorbance at 340 nm with a spectrophotometer (model DU 640, Beckman). Measurement of reduction of light absorption by NADH at 340 nm was considered equivalent to the hydrolysis of ATP by SERCA2a activity. Membranes were incubated in buffer containing 21 mmol/l MOPS, 4.9 mmol/l NaN 3 , 0.06 mmol/l EGTA, 100 mmol/l KCl, 3 mmol/l MgCl 2 , 0.2 mmol/l NADH, 1 mmol/l phosphoenolpyruvate, 8.4 units of pyruvate kinase, and 12 units of lactate dehydrogenase. The reaction was started with ATP (1 mmol/l) and was performed at 37°C. SERCA2a activity was calculated from the change of absorption at 340 nm divided by the extinction coefficient of NADH (6.22 cm 2 ·µmol Ϫ1 ·mg protein Ϫ1 ·min Ϫ1 ). Basal activity was measured in Ca 2ϩ -free buffer in the presence of EGTA (4 mmol/l) and then in ascending Ca 2ϩ concentrations. SERCA2a maximal turnover rate (V max ) was calculated from nonlinear regression analysis of the single Ca 2ϩ -SERCA2a activity curves with Prism software.
Western Blot Analysis
For the detection of proteins, we performed immunoblots in homogenates according to Towbin et al. (30) with modifications as previously described (20) . Preparations were thawed on ice, suspended in buffer (0.5 mmol/l Tris · HCl, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, and 0.05% bromphenol blue) without boiling of membrane preparations. Protein separation was performed in a discontinuous SDS-polyarcylamide gel with 4% stacking gel and 12% separation gel (SE 600, Hoefer Scientific Instruments, San Francisco, CA) under constant current of 60 and 100 mA. Protein transfer to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad Laboratories, Hercules, CA) was achieved with 80-mA constant current at 4°C overnight with a Hoefer Transphor unit. Transfer efficiency was verified by total protein staining of the gels with Coomassie blue. Membranes were blocked in Trisbuffered saline containing 5% milk. Antibody binding on the PVDF membrane with specific antibodies was performed overnight at 4°C. After thorough washing procedures, the membrane was exposed to the secondary antibody, a peroxidase-conjugated anti-mouse IgG or anti-rabbit monoclonal antibody, for 2 h at room temperature. For detection of antibody binding, an enhanced chemiluminescence assay (ECL kit, Amersham Life Science, Buckinghamshire, UK) was used. PVDF membrane was exposed to an X-ray film (Amersham) according to the signal. Quantification of protein expression was achieved after films were scanned into a personal computer, and densitometric volume of bands was analyzed with a commercially available computer program (IQant).
Statistical Analysis
Values are means Ϯ SE of 12 DCM and 12 NF hearts. SERCA2a activity (in nmol ATP hydrolyzed · mg protein Ϫ1 · min Ϫ1 ) is given as the mean of 12 NF and 12 DCM hearts. Densitometric units were normalized to protein concentration applied per slot and expressed as densitometric units per microgram of protein. Protein expression of SERCA2a and phospholamban was also normalized to calsequestrin expression as an internal protein standard and expressed as SERCA2a-to-phospholamban or phospholamban-to-calsequestirn ratio. For optimal frequency and maximal tension development in the FFR, the respective frequency or maximal tension as change in maximal developed tension (⌬mN) was determined by manual analysis of the FFR curves. Correlation between optimal stimulation frequency and maximal force development was determined by linear regression analysis with Prism software. Differences between groups were compared with a two-way ANOVA, and P Ͻ 0.05 was considered significant.
Materials
Salts were high grade and were purchased from Merck (Darmstadt, Germany); PIPES, MOPS (99.5%), phenylmethylsulfonyl fluoride, and Ca 2ϩ ionophore A-23187 were obtained from Sigma Chemical (St. Louis, MO) and 30% acrylamide/bisacrylamide from Bio-Rad. Primary antibodies against SERCA2a were mouse monoclonal IgG1 antibodies against canine SERCA2a protein (ABR, Affinity Bioreagents, Golden, CO). Antibodies against phospholamban were mouse monoclonal IgG antibodies against canine phospholamban (Upstate Biotechnology, Lake Placid, NY). Polyclonal rabbit antibodies against canine calsequestrin were acquired from SWant (Bellizona, Switzerland). Phosphoantibodies against Ser 16 and Thr 17 phospholamban (PhosphoProtein Research, West Yorkshire, UK) are polyclonal mouse anti-canine IgG antibodies, which selectively bind to the phosphorylated form only and specifically distinguish the amino acids Ser 16 and Thr 17 , respectively (5). Secondary antibodies were peroxidaseconjugated monoclonal sheep anti-mouse IgG and peroxidaseconjugated goat anti-rabbit IgG (Sigma Immunochemicals, St. Louis, MO).
RESULTS
The total protein yield for crude membrane preparations was 1.59 Ϯ 0.23 and 1.57 Ϯ 0.27 mg/g tissue wet wt in NF and DCM hearts, respectively. There was no apparent difference in the protein yield from NF and DCM hearts. The protein yield for homogenates was also similar in NF and DCM preparations (126.3 Ϯ 7.3 and 121.5 Ϯ 11.7 mg/g tissue for NF and DCM, respectively).
Comparison Between RA and LV SERCA2a activity. In NF control hearts, no difference in SERCA2a V max was found between preparations from LV and RA ( Fig. 1 ; 253 Ϯ 10 and 286 Ϯ 19 nmol ATP · mg protein Ϫ1 · min Ϫ1 for LV and RA, respectively). In DCM hearts, SERCA2a V max was significantly (P Ͻ 0.0001) increased in preparations from the RA in comparison to the LV (196 Ϯ 11 and 396 Ϯ 30 nmol ATP·mg protein Ϫ1 · min Ϫ1 for LV and RA, respectively; Fig. 1 ).
Immunoblots. The chemiluminescence signal for the binding of specific antibodies to SERCA2a and phospholamban, depending on the protein application, was tested from 5 to 100 µg of protein per slot. Over a wide range of protein applied, the densitometric signal was linear, with a regression coefficient between 0.92 and 0.98, as previously shown (20) .
Ten micrograms of protein were applied in the assay to study protein expression of SERCA2a and phospholamban in NF and DCM hearts to compare RA and LV protein expression. SERCA2a expression normalized to protein was similar in LV and RA of NF (19 Ϯ 2 and 21 Ϯ 3 densitometric units in LV and RA, respectively) and DCM myocardium (20 Ϯ 2 and 20 Ϯ 2 densitometric units in LV and RA, respectively; Fig. 2 ). Phospholamban expression normalized to protein was significantly higher in LV than in RA of NF hearts (16 Ϯ 2 vs. 12 Ϯ 3 densitometric units) and slightly lower in LV than in RA from DCM tissue (18 Ϯ 3 vs. 23 Ϯ 5 densitometric units; Fig. 2 ).
When protein expression of SERCA2a was normalized to calsequestrin protein as an internal standard for overall protein expression, SERCA2a expression was also unchanged in the LV compared with the RA in NF (3.9 Ϯ 0.3 and 3.2 Ϯ 0.4 densitometric units in LV and RA, respectively) and DCM hearts (4.8 Ϯ 0.8 and 3.4 Ϯ 0.1 densitometric units in LV and RA, respectively). In contrast, in NF hearts, phospholamban expression normalized to calsequestrin was significantly higher in LV than in RA (3.0 Ϯ 0.5 vs. 1.7 Ϯ 0.3 densitometric units), whereas in DCM tissue, no statistical difference was apparent (4.5 Ϯ 1.3 and 3.7 Ϯ 0.6 densitometric units in LV and RA, respectively).
Normalization of SERCA2a to phospholamban resulted in lower ratios in LV than in RA from NF hearts There was marked reduction of the phosphorylation at Ser 16 of phospholamban in RA compared with LV in the NF and the DCM groups (Fig. 3) . Phosphorylation at Thr 17 of phospholamban was also lower in RA than in LV of NF (174.6 Ϯ 11.2 vs. 37.4 Ϯ 8.9) and DCM hearts (131.2 Ϯ 10.9 vs. 9.2 Ϯ 2.4; Fig. 3 ).
The ratio of phosphorylated phospholamban at Ser 16 was significantly higher in LV than in RA of the NF (18.0 Ϯ 3.2 vs. 6.1 Ϯ 0.7) and DCM groups (14.8 Ϯ 2.8 vs. 3.9 Ϯ 0.4). The same is also true for Thr 17 phosphorylation. A higher fraction of phosphorylated phospholamban in LV than in RA was found at Thr 17 increased with increasing stimulation parameters. However, contraction and relaxation were significantly faster in RA than in LV.
In contrast, LV muscle preparations from DCM hearts developed a negative FFR from 0.5 to 3.0 Hz frequency. The force of contraction declined from 1.5 Ϯ 0.2 mN at 0.5 Hz to 0.5 Ϯ 0.1 mN at 3.0 Hz. In isolated muscle strips from the RA from DCM hearts, the force of contraction increased steadily from 1.2 Ϯ 0.2 mN at 0.5 Hz over the whole range of frequencies to 2.5 Ϯ 0.5 mN at 3.0 Hz (Figs. 4 and 5) . The contraction and relaxation velocities in LV myocardium from DCM hearts did not increase with increasing stimulation frequencies (ϩT: 10.8 Ϯ 1.7 and 11.0 Ϯ 2.5 mN/s at 0.5 and 3.0 Hz, respectively) or even decreased (ϪT: 8.2 Ϯ 2.7 and 5.9 Ϯ 1.8 mN/s at 0.5 and 3.0 Hz, respectively). In contrast, RA contraction parameters in DCM hearts increased gradually over the range of stimulation frequencies (ϩT: 21.3 Ϯ 0.8 and 57.3 Ϯ 7.5 mN/s at 0.5 and 3.0 Hz, respectively; ϪT: 10.6 Ϯ 0.4 and 41.6 Ϯ 5.2 mN/s at 0.5 and 3.0 Hz, respectively). When contraction and relaxation velocities in the DCM group were compared, RA contracted significantly faster than LV in DCM hearts, and contraction and relaxation gradually increased in RA and decreased in LV from DCM hearts.
Comparison Between NF and DCM Hearts
SERCA2a activity. SERCA2a V max in preparations from LV was significantly (P Ͻ 0.001) reduced in DCM tissue preparations compared with NF control tissue (253 Ϯ 10 vs. 196 Ϯ 11 nmol ATP · mg protein Ϫ1 · min Ϫ1 ). In contrast, V max of SERCA2a was significantly increased (P Ͻ 0.05) in RA from DCM preparations Fig. 4 . Representative original twitch recordings from human myocardium after increase of stimulation frequency from 0.5 to 3 Hz. Slow and fast recordings are demonstrated for RA from explanted hearts from NF organ donors (RA NF) and explanted hearts from patients undergoing cardiac transplantation due to terminal heart failure (RA DCM) and from LV from explanted hearts of NF organ donors (LV NF) and from patients with terminal heart failure due to DCM undergoing cardiac transplantation (LV DCM). Time course and force generation are indicated by horizontal and vertical bars, respectively. compared with RA from NF controls (286 Ϯ 19 vs. 396 Ϯ 30 nmol ATP · mg protein Ϫ1 · min Ϫ1 ; Fig. 1) .
Immunoblots. In a comparison of SERCA2a protein expression in NF and DCM preparations, no significant differences were found in LV (19 Ϯ 2 and 20 Ϯ 2 densitometric units in NF and DCM, respectively) or RA (21 Ϯ 3 and 20 Ϯ 2 densitometric units in NF and DCM, respectively; Fig. 2 ). When phospholamban protein expression was compared in NF and DCM hearts, protein expression was unchanged in LV myocardium (16 Ϯ 2 and 18 Ϯ 3 densitometric units in NF and DCM, respectively), but phospholamban expression was significantly increased in DCM RA compared with NF RA (12 Ϯ 3 vs. 23 Ϯ 5 densitometric units). Calsequestrin protein expression was unchanged in NF compared with DCM preparations in LV and RA myocardium (5 Ϯ 1 and 7 Ϯ 1 densitometric units in NF LV and RA, respectively, and 4 Ϯ 1 and 6 Ϯ 1 densitometric units in DCM LV and RA, respectively). When immunoblots were normalized to calsequestrin as internal standard, comparison of NF and DCM preparations showed unchanged SERCA2a expression normalized to calsequestrin in LV (3.9 Ϯ 0.3 and 4.8 Ϯ 0.8 densitometric units in NF and DCM, respectively) and RA (3.2 Ϯ 0.4 and 3.4 Ϯ 0.1 densitometric units in NF and DCM, respectively). Comparison of NF and DCM hearts showed unchanged phospholamban expression normalized to calsequestrin in LV (3.0 Ϯ 0.5 and 4.5 Ϯ 1.3 densitometric units in NF and DCM, respectively) and RA (1.7 Ϯ 0.3 and 3.7 Ϯ 0.6 densitometric units in NF and DCM, respectively). Comparison of the NF and DCM groups showed that the differences in SERCA2a-to-phospholamban ratios did not reach significant levels in RA or LV.
Phosphorylation of phospholamban at Ser 16 was lower in DCM than in NF hearts in LV (180.5 Ϯ 19.0 vs. 132.0 Ϯ 5.4) and RA (56.8 Ϯ 6.0 vs. 22.4 Ϯ 3.5; Fig. 3 ). Phosphorylation at Thr 17 of phospholamban was also lower in both RA and LV in DCM than in NF hearts (174.6 Ϯ 11.2 and 131.2 Ϯ 10.9 in LV in NF and DCM, respectively, and 37.4 Ϯ 8.9 and 9.2 Ϯ 2.4 in RA in NF and DCM, respectively; Fig. 3) . Moreover, the ratio of phosphorylated phospholamban at Ser 16 was significantly lower in the DCM group in the LV (18.0 Ϯ 3.2 and 14.8 Ϯ 3.9 in NF and DCM, respectively) and RA (6.2 Ϯ 0.7 and 3.9 Ϯ 0.4 in NF and DCM, respectively). The optimal stimulation frequency for the force development was significantly higher in DCM than in NF control atria (1.5 Ϯ 0.8 and 3.0 Ϯ 0.4 Hz in NF and DCM RA, respectively). In LV the optimal stimulation frequency for developed tension was significantly higher in NF than in DCM muscle strips (2.5 Ϯ 0.7 vs. 0.7 Ϯ 0.9 Hz). Moreover, maximal tension was unchanged in NF RA compared with DCM RA (0.97 Ϯ 0.28 and 1.3 Ϯ 0.02 ⌬mN in NF and DCM RA, respectively). In contrast, in DCM LV, maximal tension was significantly reduced compared with NF LV (1.26 Ϯ 0.25 vs. 0.02 Ϯ 0.01 ⌬mN). Good correlation was found between FFR parameters and SERCA2a activity. When the NF and DCM groups are taken together, the correlation between optimal stimulation frequency and SERCA2a V max was 0.47 in LV (P ϭ 0.0004) and 0.62 in RA (P Ͻ 0.0001). The correlation between maximal tension development and SERCA2a V max was 0.61 in LV (P Ͻ 0.0001) and 0.38 in RA (P ϭ 0.0021) from the NF and DCM groups taken together (Fig. 6) . Moreover, good correlation between SERCA2a V max and contraction and relaxation parameters was found (r 2 ϭ 0.28, P ϭ 0.007 for ϩT; r 2 ϭ 0.19, P ϭ 0.03 for ϪT).
DISCUSSION
SERCA2a Activity and FFR
Comparison of RA and LV. A novel finding of the present study is that the FFR in the LV and RA of failing and nonfailing myocardium is tightly correlated to altered SERCA2a activity in the different chambers of the human heart. The FFR in nonfailing hearts was positive in RA and LV; however, in failing hearts the negative response of the force generation to increasing heart rates in the LV stands in contrast to a positive FFR in RA. Altered FFR parameters correlated with SERCA2a activity, which was increased solely in RA compared with LV of failing hearts but not in RA compared with LV of nonfailing hearts. The original finding of the present study is that different activity of SERCA2a in different heart chambers of the failing heart can be explained, at least partly, by a decrease of the phosphorylation status of the regulatory protein phospholamban.
In both chambers of the nonfailing hearts, a positive FFR was documented, in accordance with previous studies (8, 25, 26) . It is generally accepted that the ability of the heart to increase force generation with increasing heart rates is tightly coupled to the removal of Ca 2ϩ from the cytoplasm of the myocyte into the SR by SERCA2a (7, 9, 27) . The positive FFR was in accordance with comparable SERCA2a activity in RA and LV from nonfailing hearts. However, the maximal increase in force generation was achieved at lower stimulation frequencies in RA than in LV of nonfailing hearts. This difference in the FFR in nonfailing atrial vs. ventricular myocardium might not be explained completely by differences in SERCA2a function. Besides removal of Ca 2ϩ from the cytoplasm into the SR, transsarcolemmal Ca 2ϩ transport via the Na ϩ /Ca 2ϩ exchanger might play a role. A prominent role of the Na ϩ /Ca 2ϩ exchanger in the action potential in human atrial myocardium has been reported in an electrophysiological study (1) . Additionally, Ca 2ϩ influx into the cell and properties of the contractile system might be of importance for the FFR of the heart. Differences in Ca 2ϩ current of the L-type Ca 2ϩ channels between the atrial and the ventricular myocardium have been reported (16) and might also contribute to the differences in atrial FFR.
Although hemodynamic differences exist between RA and LV in patients with terminal heart failure, we have evidence of failure from the echocardiographic and hemodynamic data of increased chamber diameters and increased pressures in RA and LV of the failing heart. Nevertheless, besides a negative FFR in LV myocardium from failing hearts, the RA increased force generation with an increase of the stimulation frequency, in accordance with previous findings (8, 25, 26) . The FFR parameters were in good agreement with increased SERCA2a function in RA compared with LV from failing hearts. The underlying cause for the increase of SERCA2a function could not be resolved in the present study. Changes in SERCA2a or phospholamban protein expression could not help explain the change in SERCA2a regulation. Phosphorylation of Fig. 6 . Correlation between contractile parameters of force-frequency relation and SERCA2a V max in human myocardium. Left: RA myocardium; right: LV myocardium. Top: correlation between SERCA2a V max and optimal stimulation frequency in force-frequency relation that elicits maximal tension development in multicellular human myocardial preparations. Correlation coefficient (r 2 ) ϭ 0.62 (P Ͻ 0.0001) in RA and 0.47 (P ϭ 0.0004) in LV myocardium. Bottom: correlation between SERCA2a V max and maximal force generation in force-frequency relation in multicellular human myocardial preparations; r 2 ϭ 0.38 (P ϭ 0.0021) in RA, and r 2 ϭ 0.61 (P Ͻ 0.0001) in LV.
phospholamban relieves the inhibitory action of phospholamban on SERCA2a activity (29) . However, phosphorylation of the regulatory protein phospholamban could not explain the altered SERCA2a function, inasmuch as phospholamban phosphorylation was markedly lower in RA than in LV from failing hearts. Possibly direct phosphorylation of SERCA2a (31, 34) might play a role in increased SERCA2a activity and positive FFR in atria from failing hearts. Besides changes in the Ca 2ϩ homeostasis of the failing heart, Ca 2ϩ sensitivity of myofibrils might also influence the FFR of LV and RA. Decreased Ca 2ϩ sensitivity of the contractile apparatus in atria vs. ventricles in failing hearts as a result of different myosin isozyme expression has been reported (32) .
Comparison of failing and nonfailing myocardium. It is well documented that muscle strips of LV from failing myocardium develop a negative FFR (11, 19, 24, 26) . The present data underline the importance of SERCA2a activity for the contractile parameters of the FFR not only in LV, but also in RA, from failing hearts. A decrease of SERCA2a activity was found in LV from failing hearts in comparison to nonfailing controls in the present study. This again is in accordance with previous findings concerning the decreased Ca 2ϩ uptake (9, 14, 27) and reduced function of SERCA2a in failing human ventricles (27) . Functional alterations of SERCA2a in failing LV can be explained by different phosphorylation status of phospholamban, leading to an increased inhibition of SERCA2a in failing myocardium (11, 18) . Recently, Schwinger et al. (23) showed lower PKA-dependent phosphorylation at Ser 16 of phospholamban in failing human cardiac preparations, which contributes to the decreased Ca 2ϩ sensitivity of SERCA2a. The importance of phosphorylation for the regulation of SERCA2a was underlined in the present study. A novel finding is lower phosphorylation at the PKA-dependent Ser 16 site and the calmodulin kinasedependent Thr 17 site of phospholamban in failing LV myocardium, which explains the reduced SERCA2a in failing LV compared with nonfailing LV.
The importance of SERCA2a activity for FFR could be demonstrated by good correlations between SERCA2a V max and FFR parameters such as tension development, optimal stimulation frequency, and cycle parameters such as contraction and relaxation velocity. In recent work from our laboratory, it could be demonstrated that, even in nonfailing tissue, force frequency depends on SERCA2a activity (28) . Inhibition of SERCA2a by cyclopiazonic acid in nonfailing myocardium from LV papillary muscle strips mimics the negative FFR found in terminally failing human myocardium.
The FFR in RA tissue from failing hearts was positive and, compared with RA from nonfailing hearts, shifted to higher frequencies in accordance with increased SERCA2a activity. Thus the ability of the myocardium to increase the force of contraction at higher heart rates seems to be very closely linked to SERCA2a activity in atria and ventricles, even in diseased myocardium. A previous report emphasizes the importance of the SERCA2a-to-phospholamban ratio for myocardial contractility (13); however, the present data do not support this hypothesis, inasmuch as the highest SERCA2a-tophospholamban ratio was found in atria from nonfailing hearts, whereas the highest SERCA2a activity was found in atria from failing hearts.
In contrast to the reduction of phospholamban phosphorylation in LV myocardium in patients with DCM, the increase in SERCA2a in RA from patients with DCM cannot be explained by the phosphorylation of phospholamban. However, direct regulation of SERCA2a activity, independent of phospholamban, could also be present. Whether phosphorylation of SERCA2a is direct is under debate and has not been resolved (21, 22, 31, 34) . Thus, in RA myocardium, not only the phosphorylation status or the protein expression of phospholamban, but a direct modification of SERCA2a function, might explain differences in SERCA2a regulation. In addition to altered SERCA2a function, different Ca 2ϩ sensitivity of the contractile proteins due to different phosphorylation of troponin I additionally affects the FFR in failing human myocardium (33) .
Conclusion
SERCA2a function is a major determinant for the FFR in human myocardium. Marked differences in SERCA2a activity and FFR are present in LV and RA from terminally failing human hearts. Changes in SERCA2a in LV from failing hearts can be at least partly explained by lower phosphorylation of phospholamban. Changes in SERCA2a function in atria from failing human hearts are not due to changes in phospholamban protein expression or phosphorylation and, hence, may be indicative of an altered direct SERCA2a regulation.
Limitations of the Study
The alteration in FFR in LV myocardium is a welldocumented phenomenon. It is widely accepted that alterations of Ca 2ϩ homeostasis of the failing myocardium play a key role in the negative FFR in LV from terminally failing human hearts. However, data on FFR in different chambers of the failing heart, particularly in RA of hearts from patients with DCM, are sparse. The present study confirms previous findings of FFR and SERCA2a in LV of hearts from patients with DCM but gives new insights into the activity and regulation of SERCA2a and phospholamban in RA from terminally failing human hearts. This study gives new evidence that phosphorylation of phospholamban plays an important role in SERCA2a regulation but also raises questions concerning different modulatory aspects of SERCA2a function in human atrial myocardium.
